Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Magnetic Resonance in Medical Sciences : MRMS : an Official Journal of Japan Society of Magnetic Resonance in Medicine|May 17, 2021
Combining the Tumor Contact Length and Apparent Diffusion Coefficient Better Predicts Extraprostatic Extension of Prostate Cancer with Capsular Abutment: A 3 Tesla MR Imaging StudyKoichi Ito, Emiko Chiba, Noriko Oyama-Manabe, et al.
European Journal of Pharmacology|March 12, 2013
α-Lipoic acid protects against arsenic trioxide-induced acute QT prolongation in anesthetized guinea pigsMasafumi Kumazaki, Hitoshi Ando, Masafumi Kakei, et al.
Hinyokika Kiyo. Acta Urologica Japonica|November 1, 2023
[A Case of Left Renal Cell Carcinoma with Renal Arteriovenous Fistula and Multiple Vascular Malformation Undergoing Nephrectomy]Takanori Hayase, Satoshi Washino, Hiroki Yagi, et al.
BMC Endocrine Disorders|April 26, 2022
Hypereosinophilia is a predictive biomarker of immune checkpoint inhibitor-induced hypopituitarism in patients with renal cell carcinomaHodaka Yamada, Satoshi Washino, Daisuke Suzuki, et al.
Diseases (Basel, Switzerland)|April 25, 2025
Neoadjuvant Chemohormonal Therapy Versus Pelvic Lymphadenectomy on Biochemical Recurrence in Patients with High- or Very-High-Risk Prostate Cancer Undergoing Robot-Assisted Radical ProstatectomyMakoto Kawase, Satoshi Washino, Takato Nishino, et al.
Clinical Genitourinary Cancer|April 30, 2025
Efficacy of Neoadjuvant Hormonal Therapy for High-Risk Prostate Cancer Undergoing Robot-Assisted Radical Prostatectomy: A Retrospective Multicenter Study Using Propensity Score-Matched Analysis in JapanMinori Nezasa, Makoto Kawase, Satoshi Washino, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|December 21, 2022
Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective studyKeita Izumi, Masaharu Inoue, Satoshi Washino, et al.
Urologic Oncology|November 19, 2025
Clinical outcomes of retreatment or discontinuation after interruption of nivolumab plus ipilimumab due to immune-related adverse events in metastatic renal cell carcinoma patients: A retrospective multicenter studyYuta Sano, Masaharu Inoue, Satoshi Washino, et al.
Molecular Cancer Research : MCR|July 14, 2019
Loss of MAP3K7 Sensitizes Prostate Cancer Cells to CDK1/2 Inhibition and DNA Damage by Disrupting Homologous RecombinationSatoshi Washino, Leah C Rider, Lina Romero, et al.
International Journal of Clinical Oncology|July 24, 2024
Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumabTakayuki Nakayama, Hideki Takeshita, Makoto Kagawa, et al.
Pageof 6